US · HIND
Vyome Holdings, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Princeton, NJ 08540
- Website
- vyometx.com
Price · as of 2024-12-31
$1.96
Market cap 19.02M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $36,131.35 | +1,843,336.22% |
| Intrinsic Value(DCF) | $36.20 | +1,746.94% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $0.00 | ||||
| 2016 | $79,953,000.00 | $31,981,337.83 | $0.00 | ||
| 2017 | $37,062,000.00 | $14,904,553.22 | $5,904,910.09 | $0.00 | $0.00 |
| 2018 | $14,964,000.00 | $5,985,600.00 | $0.00 | $0.00 | $392,883,151.37 |
| 2019 | $983,100.00 | $16,495,766.40 | $2,900,355,561.85 | $0.00 | $0.00 |
| 2020 | $3,306,000.00 | $9,119,016.60 | $229,252.72 | $0.00 | $8,035,249.75 |
| 2021 | $261,000.00 | $125,568.35 | $182,207.88 | $0.00 | $0.00 |
| 2022 | $19,430.00 | $10,550.91 | $0.00 | $0.00 | $1,344,191.89 |
| 2023 | $974.40 | $34,207.52 | $405.99 | $0.00 | $37,924.12 |
| 2024 | $90.50 | $36,131.35 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Vyome Holdings, Inc.'s (HIND) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $36,131.35
- Current price
- $1.96
- AI upside
- +1,843,336.22%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$36.20
+1,746.94% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| HIND | Vyome Holdings, Inc. | $1.96 | 19.02M | +1,843,336% | +1,747% | — | — | -0.26 | -7.38 | 0.23 | -0.32 | — | -7.38 | 63.17% | -96.53% | -89.06% | -222.46% | -647.51% | -91.88% | -3.82 | — | 0.92 | 0.35 | -0.04 | -8753.00% | -774.00% | -7396.00% | -237.21% | -0.89 | -370.93% | 0.00% | 0.00% | 0.00% | -0.28 | -0.48 | 0.27 | -191.26 |
| CCCC | C4 Therapeutics, Inc. | $2.70 | 192.18M | +704% | -21% | — | — | -2.50 | 1.02 | 7.31 | -0.72 | — | 1.02 | 77.81% | -290.68% | -292.08% | -44.44% | -199.27% | -29.63% | 0.23 | — | 7.81 | 7.60 | 0.14 | -1645.00% | 102.00% | 5198.00% | -37.79% | -2.99 | -189.38% | 0.00% | 0.00% | 9.54% | -0.71 | -0.75 | 2.06 | -1.45 |
| CDXS | Codexis, Inc. | $1.01 | 91.23M | +2,411% | +12% | — | +481% | -3.17 | 3.09 | 3.49 | -3.31 | — | 3.21 | 72.55% | -98.61% | -109.99% | -85.03% | -128.77% | -45.72% | 0.89 | — | 4.18 | 3.90 | -0.69 | -2054.00% | -1539.00% | -586.00% | -25.95% | -2.09 | -118.20% | 0.00% | 0.00% | 0.00% | -3.31 | -3.60 | 3.26 | -4.07 |
| CGEN | Compugen Ltd. | $1.81 | 169.3M | +2,407% | -50% | — | -30% | -10.44 | 2.71 | 5.33 | -3.35 | — | 2.71 | 71.54% | -53.44% | -51.07% | -23.63% | 101.98% | -12.04% | 0.05 | -437.97 | 5.26 | 5.14 | 1.06 | -2381.00% | -1672.00% | -23724.00% | 33.30% | 2.46 | -338.90% | 0.00% | 0.00% | 1.87% | -3.24 | 0.98 | 1.73 | -3.76 |
| IMDX | Insight Molecular Diagnos… | $6.01 | 172.27M | +228% | -74% | — | — | -0.84 | -4.15 | 27.10 | -0.78 | -3.46 | -1.90 | 39.34% | -3245.14% | -3225.04% | -1480.67% | 3654.06% | -110.32% | -0.30 | -726.68 | 1.62 | 1.41 | 0.08 | 2430.00% | 2515.00% | -1007.00% | -41.64% | -2.85 | 1270.82% | 0.00% | 0.00% | 0.00% | -0.75 | -2.17 | 24.46 | -18.88 |
| IPHA | Innate Pharma S.A. | $1.72 | 160.74M | +2,263% | -50% | — | +2,571% | -2.98 | 16.70 | 11.69 | -2.08 | -0.52 | 16.70 | 100.00% | -408.64% | -391.97% | -162.91% | 247.94% | -34.57% | 3.51 | -91.12 | 2.60 | 2.50 | 0.75 | 57778.00% | -7568.00% | -7913.00% | -4.94% | -0.21 | 35.03% | 0.00% | 0.00% | 3.18% | -1.90 | -13.41 | 7.74 | -4.85 |
| NVCT | Nuvectis Pharma, Inc. | $8.86 | 234.72M | — | — | — | — | -7.46 | 10.71 | — | -6.00 | -39.42 | 10.71 | 0.00% | — | — | -188.03% | 250.21% | -105.10% | 0.00 | — | 2.38 | 2.38 | 1.15 | 1892.00% | — | 3072.00% | -8.12% | -1.20 | 145.27% | 0.00% | 0.00% | 6.64% | -6.00 | -10.34 | — | 2.32 |
| OABI | OmniAb, Inc. | $1.72 | 185.11M | +16,336% | +3% | — | +382% | -5.61 | 1.21 | 13.19 | -6.12 | -28.61 | 5.31 | 100.00% | -282.30% | -235.05% | -20.60% | -25.66% | -17.70% | 0.08 | — | 4.52 | 4.29 | 0.09 | 1961.00% | -2275.00% | -600882.00% | -11.94% | -2.63 | -16.47% | 0.00% | 0.00% | 3.92% | -4.18 | -7.51 | 11.81 | 4.59 |
| SGMO | Sangamo Therapeutics, Inc… | $0.43 | 160.68M | +6,900% | -3% | — | +6,207% | -2.14 | 9.21 | 3.63 | -2.23 | — | 9.21 | 100.00% | -179.88% | -169.45% | -185.39% | -403.81% | -73.38% | 1.34 | — | 1.13 | 1.02 | 0.13 | -6689.00% | -6720.00% | -7260.00% | -32.13% | -1.47 | -262.24% | 0.00% | 0.00% | 2.03% | -1.91 | -2.94 | 3.43 | -21.86 |
| TNXP | Tonix Pharmaceuticals Hol… | $13.97 | 178.65M | -2% | -63% | — | — | -0.23 | 0.21 | 2.92 | 0.86 | — | 0.21 | 23.07% | -1354.28% | -1288.25% | -106.12% | -200.34% | -81.95% | 0.04 | — | 6.50 | 5.83 | 1.26 | -9723.00% | 2994.00% | -4445.00% | -207.14% | -3.33 | -89.46% | 0.00% | 0.00% | 265.83% | 0.47 | 1.05 | -6.34 | -7.49 |
About Vyome Holdings, Inc.
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Princeton, New Jersey.
- CEO
- Venkateswarlu Nelabhotla
- Employees
- 18
- Beta
- 1.50
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($36.20 ÷ $1.96) − 1 = +1,746.94% (DCF, example).